Carvolix

Historical price data

Carvolix is a publicly traded French MedTech company founded by Truffle Capital with the ambition to become a global leader in treating structural heart disease and ischemic stroke. The company leverages a unique business builder model, integrating three synergistic entities (Caranx Medical, Artedrone, and its legacy business) to develop AI- and imaging-driven mini-robots and next-generation heart valves. With its first product, TAVIPILOT Soft, already FDA-cleared and in commercial use, and a robotic system in clinical trials, Carvolix is positioned to address massive treatment gaps in TAVI, mitral regurgitation, and mechanical thrombectomy.

AI- and imaging-driven mini-robotic platform providing supervised autonomy for complex cardiac and neurovascular interventions, designed to augment interventional cardiologists with precision guidance and control.

Carvolix competes in segments of the structural heart and neurovascular markets against giants like Edwards Lifesciences and Medtronic, as well as robotics specialists like Intuitive Surgical. Its differentiation lies in its focused 'autopilot' platform for interventional cardiologists and its strategy to democratize access rather than replace specialists.